CancerDrs

Breast Cancer clinical trials in New Hampshire

5 actively recruiting breast cancer trials at 5 sites across New Hampshire.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…

Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of …

Sponsor: Dana-Farber Cancer Institute
NCT ID: NCT04893109
Sites in New Hampshire:
  • NH Oncology-Hematology, PA - Payson Center for Cancer Care — Concord, New Hampshire
  • Dana-Farber Cancer Insitute at Londonderry Hospital — Londonderry, New Hampshire
  • Solinsky Center for Cancer Care (NH Oncology-Hematology, PA) — Manchester, New Hampshire
  • New England Cancer Specialists - Portsmouth — Portsmouth, New Hampshire
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has sprea…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03606967
Sites in New Hampshire:
  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center — Lebanon, New Hampshire
View on ClinicalTrials.gov →
NA Recruiting Network

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in New Hampshire:
  • New Hampshire Oncology Hematology PA-Concord — Concord, New Hampshire
  • Elliot Hospital — Manchester, New Hampshire
  • Solinsky Center for Cancer Care — Manchester, New Hampshire
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-01